{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000003","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.144493+00:00","generated_at":"2026-06-07T02:47:31.283290+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Boston Scientific to acquire Axonics for $3.7B, expanding urology portfolio into sacral neuromodulation","bullets":["Purchase price of $71 per share cash; equity value ~$3.7B, enterprise value ~$3.4B.","Axonics 2023 revenue ~$366M (+34% YoY); deal expected to close H1 2024.","Axonics offers SNM therapy for overactive bladder and fecal incontinence with Axonics R20 neurostimulator (20+ year battery).","Deal expected to be immaterial to BSX adjusted EPS in 2024, accretive thereafter.","Expands BSX urology portfolio into high-growth SNM adjacency, targeting ~30M OAB patients in US."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000003","json":"https://secwatch.observer/filing/0000885725-24-000003.json","markdown":"https://secwatch.observer/filing/0000885725-24-000003.md","text":"https://secwatch.observer/filing/0000885725-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/0000885725-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/bsx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:47:31.283290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}